Stoke Therapeutics
STOK
97 hedge funds and large institutions have $680M invested in Stoke Therapeutics in 2021 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 41 increasing their positions, 26 reducing their positions, and 20 closing their positions.
58% more call options, than puts
Call options by funds: $1.72M | Put options by funds: $1.09M
58% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 26
8% less funds holding
Funds holding: 106 → 97 (-9)
45% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 20
49.74% less ownership
Funds ownership: 104.81% → 55.07% (-50%)
54% less capital invested
Capital invested by funds: $1.49B → $680M (-$811M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
+$10.5M |
| 2 |
State Street
Boston,
Massachusetts
|
+$5.57M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$2.91M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.75M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$2.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$26.4M |
| 2 |
Goldman Sachs
New York
|
-$14.9M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.33M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.64M |
| 5 |
BlackRock
New York
|
-$5.11M |
STOK Hedge Fund Activity: Q2 2021 in Review
97 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q2 2021, worth a combined $680M — down 54% from $1.49B a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of STOK and 11 opened new positions — a net loss of 9 holders — while 26 trimmed existing stakes and 41 added.
The largest buyer was Octagon Capital Advisors, opening a new position worth an estimated $10.5M. The largest seller was Fidelity Investments, cutting an estimated $26.4M.
- 97 institutional investors held Stoke Therapeutics (STOK) as of Q2 2021, down from 106 in Q1 2021.
- Funds reported $680M of Stoke Therapeutics stock for Q2 2021, down 54% quarter-over-quarter.
- 11 funds opened new Stoke Therapeutics positions in Q2 2021 and 20 closed out, a net change of -9 holders.
- The largest Stoke Therapeutics buyer in Q2 2021 was Octagon Capital Advisors, an estimated $10.5M added.
- The largest Stoke Therapeutics seller in Q2 2021 was Fidelity Investments, an estimated $26.4M sold.
Based on aggregated 13F filings for Q2 2021.